Financial Implications Of Mergers

Let’s Dance: Private Equity plays a major part in the music ecosystem paying 15-25x annual cash flow for royalties. Since 2020, several billion dollars have been invested in music royalities led by the largest PE sponsors in the world, including Blackstone, Apollo Global Management, Inc., KKR, & The Carlyle Group. Francisco Partners the brilliant technology-software focused PE firm, led by Dipanjan Deb purchased a controlling stake in the best PE music specialty asset manager, Kobalt Music. Kobalt recently sold a catalogue comprised of Weeknd, Lorde and others for $1.1 billion to a KKR-led team, with another sponsor selling its music royalties (Shakira & Nelly) for $465 million. The music business has always been big business, but the original creative mind who revolutionized the monetization of music rights was Mr. Space Oddity himself, David Bowie. Bowie Bonds were the first music-backed bond sold in the capital markets, allowing the artist to receive a windfall in the 1990’s when Moody’s, S&P and Fitch rated his music-backed bonds. The bonds matured 10-years after issuance, and the rights to the income reverted to David Bowie. Thanks to the demise of Napster, and the business models of Spotify and Apple Music, top recording artists receive payment for every song played. Music royalties are classified as Master or Composition, whereby the Master is the IP or rights to reproduce or distribute the sound recording that belongs to the recording artist or record label; whereas the Composition represents the rights based on the lyrics, harmonies, or melodies of the song that belongs to the songwriter or publisher. As Prince famously said in a Rolling Stones article “if you don’t own your own masters, the master owns you”. Taylor Swift’s Eras Tour has topped $4 Billion, the most profitable in history, which comes after her legal battle with a promoter who purchased her music rights from her producer. Given the steady cashflows for royalties, financing is based on an LTV attachment point and DSCR. Financing costs have soared over the past two years, so returns are now upside down for some of the PE sponsors, with creditors earning more interest income than the royalty stream earned by equity, a condition that is not particularly favorable at this current juncture. This explains why there has been very few transactions in 2023 given costly financing. During the past two years, as interest rates have risen, the price paid for music royalty cash flow streams has fallen nearly 20%. For instance, if a buyer were to pay 20x cash flow expecting to earn a 5% return (unleveraged), and the newly adjusted multiple subsequently traded at 16x, then the value would decline by ~20% as the new buyer requires ~100bp higher yield. A publicly listed UK listed music royalty company trades at a discount to its NAV as its share price has declined 50% from 2021.

Quite crazy that YouTube accounts for 35-50% of digital revenues of India's top music labels! But the truly insane part is how this single number hides three totally different business models. The data for the recently FY25 shows a stark divide. Let me explain. .. Tips Music sources a staggering 50% of its digital revenue from YouTube - a massive bet on a single partner. - It has effectively chained its destiny to YouTube's platform - Any shift in the YouTube algorithm or a change in ad monetisation could rock their entire financial foundation .. On the other end is Saregama, the picture of stability. - They have engineered a perfect 35% / 35% balance between YouTube and other platforms - This includes major audio apps like Spotify and viral short-video apps This is a deliberate strategy to de-risk their business. By not over-relying on any one source, Saregama builds a resilient and predictable financial future. They are insulated from the shocks of any single platform's changes. .. Then you have Zee Music, which is playing for tomorrow. They are the only ones earning slightly more from Music OTTs and short-form video (40-45%) than from YouTube. This is a clear signal of their focus. Zee is targeting the Gen-Z user who lives on Instagram Reels and discovers music via curated playlists. Their strategy is built for the new age of music consumption, not the old one. It is a bet on social virality and audio streaming. .. So, this simple bar chart is not just a financial summary. It is a fascinating snapshot of each label's digital risk, and their core bet on the future. You have the high-risk YouTube loyalist, the stable diversifier, and the forward-looking trend-chaser. Amazing, no? Did you know this? .. PS: I share several biz/economy deepdives daily, with 33k+ people on WhatsApp. Do check out here: https://lnkd.in/dfWQgxKd Best, Jayant Mundhra

Bollywood’s Crown Jewels Are Being Sold, And That Tells You Everything About The Industry’s Future When Sanjay Leela Bhansali sells up to 50% of Bhansali Productions for ₹325 cr & Karan Johar exits 50% of Dharma Productions for ₹1000 cr, this isn’t a liquidity event. It’s a signal. ₹1325 cr has changed hands. For the 1st time in 100 yrs, Bollywood’s most powerful auteur-led studios are admitting family-run film empires can no longer survive on creative reputation alone. ✅ The Big Picture: Bollywood’s Old Model Is Breaking Hindi cinema today is fighting a 3-front war 1. OTT platforms absorbing audiences & capital 2. South Indian cinema dominating spectacle and scale 3. Ballooning budgets with collapsing hit rates The result is an industry bleeding ₹2800–3400 cr/ yr. • 2019 peak:₹14200 cr • 2023 recovery:₹10400 cr • Still 27% below pre-pandemic highs At the same time: 1. OTT platforms spent ₹18400 cr on content in 2023 alone 2. South cinema captured 42% of the Hindi-belt box office 3. Average Hindi film budgets jumped 68% in 5 yrs 4. Success rate collapsed from 38%→18% ✅The Deals That Changed Bollywood’s Power Map 1. Bhansali Productions×Saregama Deal Size: ₹325 cr, Stake: Up to 50%, Implied Valuation: ₹650–₹812 cr. Bhansali, the last pure auteur, chose institutional backing. - ₹180–₹250 cr film budgets can’t be self-funded anymore - OTT demands scale, pipelines & governance - Music IP+film IP integration now matters more than auteurs Saregama didn’t buy Bhansali’s past. They bought future IP, music rights, OTT pipelines & remake optionality. 2. Dharma Productions×Adar Poonawalla Deal Size:₹1000 cr, Stake: 50%, Valuation:₹2000 cr. This was succession planning disguised as a strategic deal. What Poonawalla bought • Bollywood’s most bankable brand • OTT leverage with Netflix & Disney • Talent management annuity via Dharma Cornerstone What Karan Johar secured: • Capital insulation from ₹200–₹300 cr film risks • A future-proof corporate structure • Continuity beyond the founder ✅ Let me share #Rajspectives 1. More than 60% of major studios have no clear next-generation operators. No heirs, no appetite for risk, no tolerance for public scrutiny. 2. Running a film studio today means: 82% probability of loss, ₹150–₹300 crore downside per film, zero margin for ego-driven decisions. Institutions absorb this risk. Individuals can’t. 3. Buyers are lining up now due to music+film+OTT+IP monetisation. Think Disney, not YRF. Poonawalla’s Play is Pharma cash flows→ Cultural capital→ Media empire. 4. Think Reliance, not vanity investing. This is not nostalgia buying. This is platform building. 5. When Bhansali & Karan Johar, men who once rejected studio interference, invite balance sheets into their sanctuaries, it tells you Bollywood is no longer run by stars or directors. It’s run by capital discipline. The future belongs to studios that are paranoid, partnered & platform-aligned. Everyone else becomes a footnote. #india #entertainment #business #finance

In a merger, the word “synergy” is often used to justify the deal.  In large enterprises, that synergy usually slows down at the data layer. When two organisations combine, the Board expects a unified view of customers, margins, supply chains, and risk exposure.  What they often inherit instead is a fragmented estate: multiple Snowflake environments, parallel ERP systems, legacy SQL Servers still running critical workloads, and no shared definition of basic metrics. This fragmentation is not an IT inconvenience. It is a structural drag on EBITDA. Finance teams spend months reconciling numbers instead of integrating operations.  Procurement savings remain theoretical because spend data cannot be harmonised.  Cross-sell strategies underperform because customer records do not align.  Leadership debates whose dashboard is “correct” instead of focusing on growth. It also creates 𝐀𝐈 𝐩𝐚𝐫𝐚𝐥𝐲𝐬𝐢𝐬. Enterprises talk about Copilots, GenAI layers, and agentic automation.  But you cannot deploy intelligent workflows on top of contradictory data logic.  If “Revenue” or “Margin” means something different across business units, automation only scales inconsistency. Post-merger value realisation requires a shift from moving data to governing logic. That begins with defining a shared semantic layer before merging a single table.  1. Agree on enterprise-wide definitions.  2. Assign domain accountability.  3. Rationalise overlapping platforms.  4. Decommission legacy debt rather than stacking new cloud costs on top of old architecture. True cost synergy comes from building a disciplined, scalable data foundation that supports unified reporting, controlled cloud economics, and AI readiness. Modernization in this context is about ensuring the combined enterprise operates on one coherent data engine, so the merger becomes a multiplier of value. #MergersAndAcquisitions #DataStrategy #EnterpriseAI #DigitalTransformation #DataGovernance #BusinessStrategy

Earnouts are sold as a bridge between buyer and seller. Seller gets upside if the business performs. Buyer limits downside if it doesn't. Everyone wins. Except they don't. In practice, they often become the battlefield. Earnouts are one of the most litigated areas of M&A law. They destroy relationships. They unwind deals. They cost both sides far more than the amount in dispute. Here's why they go wrong,, and how to stop it happening to you. An earnout is simple in concept: part of the purchase price is deferred and paid only if the business hits agreed targets after completion. A typical structure: £2m on day one. Up to £1m more over two years if revenue exceeds £3.5m in Year 1 and EBITDA hits 18% in Year 2. The concept isn't the problem. The detail is. Sellers want short periods, simple metrics, and operational control. They want revenue targets — not profit, which can be manipulated. They want the buyer locked out of changing the cost base without consent. Buyers want profit-based metrics. Longer periods. Freedom to run the business as they see fit. Those interests don't naturally align. And here's the thing most people miss: The buyer's biggest risk isn't paying too much. It's a founder who feels cheated, stops selling, and takes the team with them. Even if your legal position is watertight, you've probably already lost the business. More on this all week. Post 2 drops tomorrow: what the UK courts have actually decided, and why winning on breach isn't the same as winning the case. #MergersAndAcquisitions #EarnOuts #BusinessAcquisition #ImpactLawyers #SMEAdvisory

3 major MASH acquisitions in under a year. Roche, GSK, now Novo. Combined value over $9B. The market's sending a clear signal: MASH has moved from speculative to strategic necessity. Here's the competitive dynamic playing out: Novo owns GLP-1s. Wegovy and Ozempic generate tens of billions annually. MASH frequently stems from obesity. Acquiring Akero Therapeutics efruxifermin gives them both ends of the treatment spectrum. They can address the obesity AND the downstream liver damage. No one else has that combination. Roche paid $3.5B for 89Bio's pegozafermin last month. Similar mechanism to efruxifermin (FGF21 analog). They're betting on a parallel path to the same market. The clinical data showed comparable efficacy, so Roche bought its way into the race rather than starting 5 years behind. GSK grabbed Boston Pharmaceuticals experimental MASH drug for $1.2B upfront earlier this year. Different mechanism (THR-β agonist), potentially complementary to FGF21 approaches. They're hedging on mechanism diversity. What this tells us: The big pharma companies with deep metabolic disease franchises have decided MASH can't be ignored anymore. The patient population is massive (6-8% globally), growing with obesity rates, and there's almost no effective treatment currently available. The companies that waited are now paying premiums to catch up. Novo Nordisk's 16% premium looks reasonable until you factor in the 42% run-up from acquisition speculation. Roche paid a 127% premium for 89bio. GSK went straight to a $1.2B upfront payment before the asset even hit meaningful clinical milestones. Early movers got better deals. Late movers are paying for speed. The next 3-5 years will determine which mechanisms actually work in MASH. Multiple programs have failed spectacularly. The ones that succeed will define a $10B+ market. The ones that fail will write off billions in acquisition costs. But here's what's interesting: None of these companies could afford NOT to play. If MASH programs succeed and you're not in the game, you've ceded an entire treatment category to competitors. The cost of missing this market is higher than the cost of buying in. We're watching portfolio strategy play out in real time. Companies aren't just buying drugs. They're buying optionality on a market that might explode or might collapse, and they've decided the risk of missing it is worse than the cost of entry. What do you think drives the better ROI here - mechanism diversity or doubling down on proven approaches like FGF21? #Biotech #Pharma #Strategy #MASH #M&A

Music labels are taking the acquisitions and partnerships route, amid slow growth in paid subscriptions and rising content creation costs, Lata Jha reports for the Mint. This move of entering new territories and joining hands with smaller, regional players allows for collaboration with more artists, expands libraries, and helps gain a bigger share of the market, the report says. While Saregama recently acquired Haryanvi music company NAV Records, Sony Music India is turning its focus to the live music sector through a strategic joint venture with The Hello Group. Warner Music India, meanwhile, is focusing heavily on regional music. It has acquired majority stakes in South Indian label Divo, partnered with Sky Digital — a Punjabi music company — and acquired 26% of Global Music Junction, which has a strong presence in Bhojpuri, Kannada, Gujarati, Haryanvi, and Oriya music markets. “These moves illustrate how regional strengths can be scaled through strategic partnerships. They have helped unlock value by streamlining rights and royalty systems, expanding digital distribution, and bringing under-leveraged catalogues into the streaming mainstream while maintaining their cultural identity,” Believe India’s Managing Director Vivek Raina told Mint. But are there downsides to this trend? Large companies entering regional markets can create monopolies. While they may drive up costs at first by paying artists more, this may be followed by a sudden drop or adjustment in prices later, the report explains. Although there are challenges like keeping creative diversity, strategic consolidation could still promote competition, scalability, and sustainable growth in the music industry, says Hoopr’s CEO Gaurav Dagaonkar. ➡️ How will this move impact India's music industry? Share your take in the comments section. Source: Mint: https://lnkd.in/gXPGA_Vm ✍: Dipal Desai 📸: Getty Images #musiclabels

20 years in M&A have taught me a lot! However I still face numerous challenges on both the buy-side and sell-side. Here are a few: 𝗧𝗮𝗿𝗴𝗲𝘁 𝗦𝗲𝗮𝗿𝗰𝗵 Often, targets look attractive on paper but don't truly fit the buyer’s strategy, market expansion plan, capabilities, or expected synergies. 𝗣𝗿𝗲𝗽𝗮𝗿𝗶𝗻𝗴 𝗳𝗼𝗿 𝗦𝗮𝗹𝗲 The seller's primary issue is often a lack of preparation. Documentation is disorganized, finances aren't clearly presented, and there are gaps in contracts, tax issues, or corporate filings. 𝗜𝗻𝗶𝘁𝗶𝗮𝗹 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀: At this stage, the seller often struggles with how much information to disclose. Conversely, the buyer has very limited visibility and must make judgments based on incomplete or overly polished information. 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀: If EBITDA is the focus, the seller sees an opportunity to increase deal value through adjustments, while the buyer looks to decrease it. Sellers also frequently fail to grasp the critical importance of cash flow generation. 𝗗𝘂𝗲 𝗗𝗶𝗹𝗶𝗴𝗲𝗻𝗰𝗲: If I had to pick one major risk, it would be "off-balance-sheet" commitments and contingencies missing from the data room. If something is in the data room, it can be assessed or debated—but if it's missing, we might be unaware of a million-dollar liability waiting to hit us in a few years. 𝗖𝘂𝗹𝘁𝘂𝗿𝗮𝗹 𝗠𝗶𝘀𝗺𝗮𝘁𝗰𝗵: This is especially painful because it can destroy synergies even when the financial case looks rock solid. ~~~~ What are your biggest challenges? Let me know in the comments. While it's still a complex game, things are certainly easier than they were 20 years ago, we have such incredible tools at our disposal now. Here’s the rundown on Drooms for M&A, what it’s for, how it’s used: https://lnkd.in/dHhGuaYa If you have any questions, let me know.

Universal just acquired Downtown. Of course there is now a nice bump in market share but the real earthquake behind this deal is acquiring FUGA and Curve and it is going to rock the independent world. Whatever business you're in, imagine your biggest competitor taking over not only your means of getting your product to market, but also the processing system for your revenue. That is what just happened to many of the biggest independent labels. UMG now has access to the streaming performance and revenue streams of a good chunk of its competition in the indie world. FUGA and Curve are highly sophisticated tech companies that are market leaders in their space and foundations of the independent world's infrastructure. Leaders in the independent label world are going to be facing the fact that their only two options are: - Accept that UMG has taken control of their distribution and royalty processing - Rip up their infrastructure and go to a likely inferior supplier or build it yourself, which is highly disruptive even for labels who have been planning for it. Clearly neither of these options is that favourable. This is going to reverberate for a while given how essential infrastructure has become in managing the growth and complexities of data in the music industry. UMG is on a clear path to either acquiring or disrupting the infrastructure of its competition. It is exceptional strategically for UMG to the benefit of its artists and shareholders. And I'm certainly not saying that there aren't going to be benefits and synergies with FUGA and Curve in the UMG ecosystem. The reality is so many in the indie world are so explicitly anti-major that this is going to be a very hard pill to swallow. https://lnkd.in/eyCD5eed #UMG #musicindustry #Universal

Big pharma dropped $6.6B on in-vivo CAR-T startups in under a year. But this only a small niche compared to the entire Biotech M&A space. For In Vivo cell engineering From March until last October: Bristol Myers Squibb → Orbital Therapeutics ($1.5B) Gilead/Kite → Interius ($350M) + Pregene ($1.64B) AbbVie → Capstan Therapeutics ($2.1B) AstraZeneca → EsoBiotec ($1B) So why Big Pharma prefers to buy instead of build own R&D programs? Three reasons small biotechs win at innovation: #1 Cost advantage Big pharma's overhead is massive. Executive layers, complex infrastructure, global operations. A fully loaded FTE at J&J costs far more than at a 50-employee biotech. Small companies run lean and hungry. #2 Laser focus Big pharma kills programs at the first sign of trouble. "Fail early" sounds smart, but most successful drugs survived near-death moments. Small biotechs can't afford to quit. They only have 1-2 programs. That desperation breeds breakthroughs. #3 Organizational alignment Ever heard of the organizational iceberg? In large companies, only 4% of problems reach senior management. In a startup, the CEO knows everything happening at the bench. No layers. No information loss. Everyone's aligned on the mission. As a curious note you can read about the critical operational number defined by Dunbar (link below). In 2024, only 23 of 55 FDA approvals came from companies with $3B+ in sales. Small biotechs are outinnovating giants. Big pharma just figured this out. Why fund 10 risky programs internally when you can let the market fund 100 and cherry-pick the winners? It's not laziness. It's strategy. What's your take?